- In May 2024, Medidata Solutions, a Dassault Systèmes company, launched an enhanced version of its myMedidata platform featuring expanded support for licensed clinical outcome assessments across global trials. This update includes multilingual, validated eCOA instruments seamlessly integrated with eConsent and wearable data, streamlining decentralized trial execution. The launch reinforces Medidata’s commitment to delivering unified, regulatory-compliant solutions that enhance patient engagement and data integrity across therapeutic areas
- In April 2024, Signant Health announced the expansion of its licensed content library through new agreements with several PRO measure licensors. The move enables faster deployment of standardized outcome measures within its eCOA platform, particularly for oncology and CNS studies. This development underlines Signant’s strategy to strengthen its capabilities in validated data capture while reducing setup time for global trial
- In March 2024, IQVIA introduced its AI-enhanced eCOA suite integrated with licensed PROs to optimize data collection in real-world and clinical research. The platform uses predictive analytics and intelligent patient prompts to improve response rates and minimize data gaps, reflecting IQVIA’s focus on innovation and regulatory alignment in digital trials
- In February 2024, YPrime partnered with several academic institutions to deliver pre-licensed eCOA solutions for rare disease trials, accelerating study start-up and improving regulatory compliance. The collaboration enables broader access to hard-to-source outcome measures, highlighting YPrime’s commitment to expanding research capabilities in underserved therapeutic areas
- In January 2024, Clinical Ink launched a new digital platform offering turnkey access to validated, licensed eCOA instruments for use in decentralized trials. Designed to simplify global deployment, the solution includes built-in translations and automated compliance tracking, reflecting the company’s goal to make eCOA implementation more efficient, scalable, and aligned with evolving regulatory expectations
